-
公开(公告)号：EP4410836A1
公开(公告)日：2024-08-07
申请号：EP22875057.6
申请日：2022-09-29
申请人： Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group , CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
发明人： YANG, Anqi , ZHANG, Xiquan , YU, Ding , LV, Peng , WANG, Xunqiang , TIAN, Xin , CHEN, Qin
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： A61K39/395 , C07K16/28 , A61P35/00
摘要： An anti-CD47 antibody for combined treatment of a blood tumor. Provided are the use of the anti-CD47 antibody and a second therapeutic agent in the preparation of a drug for treating a blood tumor in a subject. Provided is a method for treating a blood tumor in a subject, comprising administering a therapeutically effective amount of the anti-CD47 antibody and the second therapeutic agent to a subject. Also provided are a pharmaceutical combination comprising the anti-CD47 antibody and the second therapeutic agent, and a kit.
-
公开(公告)号：EP4183421A1
公开(公告)日：2023-05-24
申请号：EP21855628.0
申请日：2021-08-13
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group
发明人： ZHANG, Xiquan , CHEN, Tianxi , FENG, Weiwei , ZHANG, Bing , TANG, Xiaoqi , XU, Tongjie , WANG, Xiaojin , SHENG, Huace , ZHANG, Zhengping , WANG, Hua , GAO, Yong
摘要： Provided is an antibody drug conjugate, specifically comprising a therapeutic antibody moiety, an intermediate linker moiety and a cytotoxic drug moiety which are linked. The therapeutic antibody moiety is an antibody against an HER2 target. The cytotoxic drug moiety is a camptothecin topoisomerase I inhibitor. The cytotoxic drug moiety or the linker-cytotoxic drug moiety is modified by means of deuterium substitution. The antibody drug conjugate can be used for the prevention or treatment of cancers.
-
公开(公告)号：EP4302763A1
公开(公告)日：2024-01-10
申请号：EP22762608.2
申请日：2022-03-03
发明人： FENG, Fan , YU, Ding , WANG, Xunqiang , ZHANG, Xiquan , BAI, Yanfeng , YANG, Chaoqiang , ZHANG, Yuying
IPC分类号： A61K31/565 , C07D403/14 , A61P35/00
摘要： The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.
-
公开(公告)号：EP4159238A1
公开(公告)日：2023-04-05
申请号：EP21817364.9
申请日：2021-06-01
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Tianjin Medical University Cancer Institute and Hospital
发明人： ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , LIU, Tao , ZHAN, Xiaole , WU, Naiying
IPC分类号： A61K39/395 , C07D215/22 , C07K16/28 , A61P35/00
摘要： Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-f luorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.
-
公开(公告)号：EP3858832A1
公开(公告)日：2021-08-04
申请号：EP19878278.1
申请日：2019-10-29
发明人： LIU, Fei , FENG, Weiwei , WANG, Bin , XU, Hongjiang , WANG, Jinan , ZHANG, Xiquan , WANG, Shanchun , LIU, Yanlong , ZHANG, Jianqing , YAO, Yiyan , TANG, Xujing , SHI, Wei , ZHANG, Hongying , LI, Yang , TANG, Song , ZHU, Yizhong , LIU, Limin , GU, Hongmei , YANG, Ling
IPC分类号： C07D471/04 , C07D211/96 , C07D215/20 , A61K31/404 , A61P35/00
摘要： Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
-
公开(公告)号：EP3590944A1
公开(公告)日：2020-01-08
申请号：EP18760796.5
申请日：2018-02-28
发明人： XIONG, Jian , XIE, Cheng , CHEN, Kevin X , XU, Xiongbin , ZHANG, Xuejin , GONG, Zhen , LI, Jian , CHEN, Shuhui , ZHANG, Aiming , JIANG, Zhulian , ZHANG, Xiquan , TIAN, Xin
摘要： Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma.
-
公开(公告)号：EP3272746B1
公开(公告)日：2019-12-25
申请号：EP16767717.8
申请日：2016-03-18
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHANG, Xiquan , TANG, Song , FENG, Weiwei , TIAN, Xin , CHEN, Zhilin , GU, Hongmei , XU, Hongjiang , LIU, Fei
IPC分类号： C07D403/12 , C07D401/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00 , A61K31/4427 , A61K45/06 , C07D239/94 , C07D211/40
-
8.发明公开
公开(公告)号：EP3502103A1
公开(公告)日：2019-06-26
申请号：EP17848166.9
申请日：2017-09-08
发明人： DING, Charles Z. , CHEN, Shuhui , HU, Lihong , XU, Zhaobing , LIU, Yingchun , REN, Bingjie , LI, Weidong , LI, Zongbin , ZHAO, Rui , ZHANG, Xiquan
IPC分类号： C07D401/14 , A61K31/506 , A61P35/00
摘要： A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.
-
公开(公告)号：EP3498704A1
公开(公告)日：2019-06-19
申请号：EP17838796.5
申请日：2017-08-11
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： SANG, Guangming , LIU, Lin , ZHANG, Aiming , QIAO, Jiabin , GUO, Xiaopeng , ZHANG, Xiquan , XIA, Chunguang
IPC分类号： C07D405/04 , A61K31/4035 , A61P5/50 , A61P3/00 , A61P35/00 , A61P25/00 , A61P3/12
摘要： The present application relates a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof.
-
公开(公告)号：EP3473626A1
公开(公告)日：2019-04-24
申请号：EP17812741.1
申请日：2017-06-15
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHOU, Zhou , ZHANG, Aiming , ZHANG, Xiquan , YAO, Huadong
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.031 秒)
